ClinicalTrials.gg
Enrolling by invitationNCT06083155NL-CFTUpdated May 14, 2024

The NetherLands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT)

An observational study in Coronary Vasospasm, Coronary Microvascular Dysfunction and Non-Obstructive Coronary Atherosclerosis, sponsored by Radboud University Medical Center. Enrolling by invitation at 15 sites in Netherlands. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Radboud University Medical Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
2,000
Sex
All
01

Study summary

The goal of this registry is to collect data on patients referred for clinically indicated coronary vasomotor function test (CFT) and answer different questions on prevalence, safety and outcomes. The registry is observational. Patients receive yearly online questionnaires on their anginal complaints for 5 years after their CFT.

02

Conditions studied

  • Coronary Vasospasm
  • Coronary Microvascular Dysfunction
  • Non-Obstructive Coronary Atherosclerosis

Browse trials for

03

In context

Coronary Vasospasm

27 studies on the registry are indexed under Coronary Vasospasm; 7 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 380 across 12 observational studies indexed under Coronary Vasospasm.

Browse Coronary Vasospasm studies →

Lead sponsor

Radboud University Medical Center is the lead sponsor of 986 studies on the registry; 135 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients referred for clinically indicated CFT are eligible

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Referred for clinically indicated CFT

Exclusion criteria

Exclusion Criteria:

  • Not willing to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Normal CFT results: no coronary vasomotor dysfunction

    Collection of data on anginal complaints, use of medication and major adverse cardiac events (MACE) by means of online patient questionnaires

    Diagnostic Test: Coronary Function Test · Other: Patient questionnaires

  • Abnormal CFT results: coronary vasomotor dysfunction

    Comparison of patient reported outcomes of different endotype groups Collection of data on anginal complaints, use of medication and MACE by means of online patient questionnaires

    Diagnostic Test: Coronary Function Test · Other: Patient questionnaires

Interventions

  • Diagnostic testCoronary Function Test

    All participants are referred for a clinically indicated coronary function test

  • OtherPatient questionnaires

    All participants that consent will receive yearly followup questionnaires for 5 years after their initial consent

06

What researchers measure

Primary outcomes

  1. Prevalence of coronary vasomotor dysfunction

    Can be handled as dichotomous outcome with normal vs abnormal coronary function test (CFT) results. Alternatively, can also be handled as categorical outcome with the following categories. 1. Normal CFT results 2. Vasospastic endotype (epicardial or microvascular); tested by acetylcholine provocation 3. Microvascular dysfunction endotype (decreased coronary flow reserve or increased index of microvascular resistance); tested by bolus thermodilution, optionallly with additional continuous thermodilution method 4. Mixed endotype

    Time frame: Baseline

Secondary outcomes

  1. Angina burden

    Measured by Seattle Angina Questionnaire summary score, 0-100 with higher scores indicating better (functional) status.

    Time frame: Baseline and every year up to 5 years after baseline

  2. Experienced quality of life

    Measured by Short Form 36, 0-100 with higher scores indicating better quality of life

    Time frame: Baseline and every year up to 5 years after baseline

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: No — Only participating centers that signed the joint data registry agreement can make a request for data after approval of steering committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2020 (actual). Primary completion is estimated for Oct 2030, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2023
First posted
Oct 13, 2023
StartActual
Oct 15, 2020
Primary completionEst.
Oct 2030
CompletionEst.
Oct 2035
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06083155
Collaborators
UMC Utrecht, Catharina Ziekenhuis Eindhoven, Maasstad Hospital, VieCuri Medical Centre, Medical Centre Leeuwarden, Haaglanden Medical Centre, Rijnstate Hospital, Medisch Spectrum Twente, Onze Lieve Vrouwe Gasthuis, Tergooi Hospital, Amphia Hospital, Elisabeth-TweeSteden Ziekenhuis, Noordwest Ziekenhuisgroep, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Oct 15, 2020
Primary completion
Oct 2030 (estimated)
Completion
Oct 2035 (estimated)
Last update
May 14, 2024

Study contacts

Peter Damman
principal investigator · Radboud University Medical Center

Oversight

FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion